Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-017140
Filing Date
2022-08-12
Accepted
2022-08-12 16:33:16
Documents
57
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20220630.htm   iXBRL 10-Q 1385094
2 EX-31.1 ikt-ex31_1.htm EX-31.1 16544
3 EX-31.2 ikt-ex31_2.htm EX-31.2 16563
4 EX-32.1 ikt-ex32_1.htm EX-32.1 14105
5 EX-32.2 ikt-ex32_2.htm EX-32.2 14105
  Complete submission text file 0000950170-22-017140.txt   4444978

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20220630_def.xml EX-101.DEF 101730
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20220630_pre.xml EX-101.PRE 204250
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20220630.xsd EX-101.SCH 35675
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20220630_lab.xml EX-101.LAB 283276
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20220630_cal.xml EX-101.CAL 26762
51 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20220630_htm.xml XML 509395
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 221160676
SIC: 2836 Biological Products, (No Diagnostic Substances)